A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity
| Autor: | S. L. Moulder, Ravi Murthy, Elizabeth A. Mittendorf, David Ramirez, GB Mills, Alastair M. Thompson, KR Hess, Marion E. Scoggins, Thorunn Helgason, V. Valero, Banu Arun, Carlos H. Barcenas, Gary J. Whitman, Beatriz E. Adrada, J. Schwartz Gomez, Jennifer K. Litton, Helen Piwnica-Worms |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment Phases of clinical research Neutropenia lcsh:RC254-282 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Breast cancer Internal medicine medicine Talazoparib Pharmacology (medical) Radiology Nuclear Medicine and imaging Chemotherapy business.industry BRCA mutation Cancer medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 3. Good health 030104 developmental biology chemistry 030220 oncology & carcinogenesis PARP inhibitor business |
| Zdroj: | npj Breast Cancer, Vol 3, Iss 1, Pp 1-6 (2017) |
| ISSN: | 2374-4677 |
| Popis: | This study was undertaken to determine the feasibility of enrolling breast cancer patients on a single-agent-targeted therapy trial before neoadjuvant chemotherapy. Specifically, we evaluated talazoparib in patients harboring a deleterious BRCA mutation (BRCA+). Patients with a germline BRCA mutation and ≥1 cm, HER2-negative primary tumors were eligible. Study participants underwent a pretreatment biopsy, 2 months of talazoparib, off-study core biopsy, anthracycline, and taxane-based chemotherapy ± carboplatin, followed by surgery. Volumetric changes in tumor size were determined by ultrasound at 1 and 2 months of therapy. Success was defined as 20 patients accrued within 2 years and |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|